Acetyl-L-carnitine for the Treatment of HIV Lipoatrophy

Annals of the New York Academy of Sciences

Volumn 1033, Issue , 2004, Pages 139-146

  Day, Larry ^a,b   Shikuma, Cecilia ^a   Gerschenson, Mariana ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b Hawaii AIDS Clin Research Program   (United States)

Author keywords

Adipose; Antiretroviral; Fat; Lipodystrophy; Nucleoside reverse transcriptase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; CARNITINE; LEVACECARNINE; NICOTINIC ACID; PIOGLITAZONE; PROTEINASE INHIBITOR; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAMINE; UBIDECARENONE; ZIDOVUDINE;

ADIPOCYTE; CARDIOVASCULAR DISEASE; CARNITINE DEFICIENCY; CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; FATTY ACID OXIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; LIPID STORAGE; MALE INFERTILITY; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; WASTING SYNDROME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 10644267458     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1320.013     Document Type: Conference Paper

References (46)

1. SCHAMBELAN, M. et al. 2002. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an Intermitional AIDS Society-USA panel. J. Acquired Immune Defic. Syndr. 31: 257-275.
2. BERNASCONI, E. et al. 2002. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J. Acquired Immune Defic. Syndr. 31: 50-55.
3. HEATH, K.V. et al. 2001. Lipodystrophy-associated morphological, cholesterol, and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15: 231-239.
4. HEATH, K.V. et al. 2002. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J. Acquired Immune Defic. Syndr. 30: 440-447.
5. THIEBAUT, R. et al. 2000. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999 Clin. Infect. Dis. 31: 1482-1487.
6. LICHTENSTEIN, K.A. et al. 2001. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15: 1389-1398.
7. SAVÉS, M. et al. 2002. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active anti-retroviral therapy. Clin. Infect. Dis. 34: 1397-1405.
8. GALLI, M. et al. 2002. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa study. Arch. Intern. Med. 162: 2621-2628.
9. GALLI, M. et al. 2003. Gender differences in antiretroviral drug-related adipose tissue alterations. J. Acquired Immune Defic. Syndr. 34: 58-61.
10. LICHTENSTEIN, K. et al. 2003. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J. Acquired Immune Defic. Syndr. 32: 48-56.
11. TIEN, P. et al. 2003. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J. Acquired Immune Defic. Syndr. 34: 461-466.
12. DURAN, S. et al. 2001. Failure to maintain long-term adherence to highly active anti-retroviral therapy: the role of lipodystrophy. AIDS 15: 2441-2444.
13. DURAN, S. et al. 2001. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin. Trials 2: 38-45.
14. JOLY, V. et al. 2002. Increased risk of lipoatrophy under stavudine in HIV-I infected patients: results of a substudy from a comparative trial. AIDS 16: 2447-2454.
15. MCCOMSEY, G. & J.F. MAA. 2003. Host factors may be more important than the choice of antiretrovirals in the development of lipoatrophy. AIDS Read 13: 539-559.
16. CARR, A. et al. 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58.
17. GALLI, M. et al. 2002. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquired Immune Defic. Syndr. 29: 21-31.
18. SAINT-MARC, T. et al. 1999. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1659-1667.
19. MALLAL, S.A. et al. 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14: 1309-1316.
20. SHIKUMA, C.M. et al. 2001. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15: 1801-1809.
21. KANNISTO, K. et al. 2003. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6, and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17: 1753-1762.
22. PACE, C.S. et al. 2003. Mitochondrial proliferation, DNA depletion, and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir. Ther. 8: 323-331.
23. DOMINGO, P. et al. 1999. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13: 2261-2267.
24. GERSCHENSON, M. 2003. Mitochondria and lipodystrophy: where are we now? Antivir. Ther. 8: 261-263.
25. CARR, A. et al. 2002. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288: 207-215.
26. SMITH, D.E. et al. 2002. Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy, but compromises antiviral control: the PIILR extension study. AIDS 16: 2489-2491.
27. HADIGAN, C. et al. 2000. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J. Clin. Endocrinol. Metab. 85: 35-41.
28. BHASIN, S. 2003. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin. Infect. Dis. 37: S142-S149.
29. ENGELSON, E.S. et al. 2002. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J. Acquired Immune Defic. Syndr. 30: 379-391.
30. SCHWARZ, J.M. et al. 2002. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 87: 942.
31. HADIGAN, C. et al. 2000. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J. Clin. Endocrinol. Metab. 85: 35-41.
32. CALMY, A., et al. 2001. A pilot study for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes. Antivir. Ther. 6: 32.
33. SUTINEN, J. et al. 2003. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir. Ther. 8: 199-207.
34. GELATO, M.C. et al. 2002. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J. Acquired Immune Defic. Syndr. 31: 163-170.
35. KELLY, G.S. 1998. L-Carnitine: therapeutic applications of a conditionally-essential amino acid. Altern. Med. Rev. 3: 345-360.
36. PATRICK, L. 2000. Nutrients and HIV: part three-N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine. Altern. Med. Rev. 5: 290-305.
37. CHAMPE, P.C. & R.A. HARVEY. 1994. Metabolism of dietary lipids. In Lippincott's Illustrated Reviews Biochemistry. Second edition, pp. 163-198. Lippincott. Philadelphia.
38. DEUFEL, T. 1990. Determination of L-carnitine in biological fluids and tissues. J. Clin. Chem. Clin. Biochem. 28: 307-311.
39. DE SIMONE, C. et al. 1992. Carnitine deficiency in AIDS patients. AIDS 6: 203-205.
40. MORETTI, S. et al. 1998. Effect of L-carnitine on human immunodeficiency virus-1-associated apoptosis: a pilot study. Blood 91: 3817-3824.
41. DI MARZIO, L. et al. 1999. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin. Immunol. 92: 103-110.
42. SCARPINI, E. et al. 1997. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J. Peripher. Nerv. Syst. 2: 250-252.
43. SIMPSON, D.M. et al. 2001. Plasma carnitine in HIV-associated neuropathy. AIDS 15: 2207-2208.
44. LOIGNON, M. & E. TOMA. 2001. L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS 15: 1194-1195.
45. DE SIMONE, C. et al. 1994. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effect of oral carnitine. AIDS 8: 655-660.
46. MAUSS, S. & G. SCHMUTZ. 2001. L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome. HIV Med. 2: 59-60.